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Neisseria meningitidis is an intracellular Gram-negative diplo-
coccus that can cause serious illnesses in children as well as
in adults. The spectrum of disease varies from a common
cold to life-threatening disorders including meningitis and/or
a fulminant septic shock. Meningococcal sepsis is charac-
terised by a sudden onset of fever and a petechial or purpuric
rash, which can be followed by hypotension and multiple
organ failure. Mortality rates can be as high as 40% [1].
Meningococcal sepsis is characterised by an exceptionally
high level of lipopolysaccharide (LPS) found in blood or cere-
brospinal fluid. Additional features of meningococal sepsis
include a severe capillary leak syndrome caused by endothe-
lial damage due to circulating mediators, neutrophils and
platelets and disseminated intravascular coagulation leading
to microthrombi. Late sequelae include skin necrosis and
occasionally the amputation of limbs.
Rates of carriage are estimated to be 10% in the general
population when cultured by nasopharyngeal swabbing, and
up to 45% when cultured from tonsillar tissue [2]. In contrast,
typical annual incidences of meningococcal disease are 5.9
per 100,000 in Ireland, 3.5 per 100,000 in The Netherlands
and 0.9–1.5 per 100,000 population in the United States
[1,3,4]. Thus, despite a high carriage rate, progression to
invasive disease occurs rarely. The clinical picture of patients
with meningococcal infections admitted to the hospital varies
from mild bacteraemia or chronic meningococcaemia to a
lethal septic shock syndrome. This raises two questions: Why
do some patients die within hours despite intensive treat-
ment? Why is meningococcal bacteraemia in other patients a
self-limiting disorder? We propose that this can be explained
by variability in host genetic factors. Convincing evidence for
the importance of the genetic background in relation to sus-
ceptibility to infectious disease was provided by Sørensen et
al. [5]. They showed that adult adoptees, of whom a biologi-
cal parent had died from an infection before the age of 50,
had a fivefold higher risk of dying from an infectious cause
than control subjects. In general, host genetic factors include
gene mutations, resulting in an absent or deficient protein,
which predisposes for disease. Gene mutations are very rare
and are estimated to be involved in less than 1% of meningo-
coccal disease cases. However, genetic polymorphisms are
stable gene variants that occur rather frequently in the
general population and do not follow simple patterns of heri-
tability. Usually they have minor effects on the regulation or
function of proteins, but these subtle changes might very well
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Abstract
This review discusses the possible involvement of a variety of genetic polymorphisms on the course of
meningococcal disease. It has been shown that several common genetic polymorphisms can either
influence the susceptibility to meningococcal disease or can account for a higher mortality rate in
patients. Gene polymorphisms concerning antibody receptors, lipopolysaccharide (LPS) binding
receptors or proteins, innate complement proteins as well as cytokines and hemostatic proteins are
described. The study of genetic polymorphisms might provide important insights in the pathogenesis of
meningococcal disease and could make it possible to identify individuals who are at risk of either
contrcting or dying from meningococcal disease.
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have important consequences for susceptibility to disease.
Furthermore, it has been shown that some genetic polymor-
phisms influence the severity of the course of a disease and
therefore can account for higher mortality rates [6]. Thus,
studying these polymorphisms might answer some of the
questions about meningococcal disease. This review
attempts to describe the current knowledge of the role of
genetic influences in severe meningococcal infections
(Fig. 1).
Colonisation and invasion
Colonisation and invasion of the nasopharyngeal mucosa are
the first steps in the pathogenesis of meningococcal disease.
In short, the filamentous pili proteins on the bacterial surface
bind to the CD46 receptor, after which Opa and Opc pro-
teins can bind to their respective receptors: CD66 and a
heparan sulphate proteoglycan receptor [7–10]. Invasion of
the mucosal cells by meningococci then occurs by endocyto-
sis [11]. Active or passive smoking is a well-known risk factor
for colonisation, but no genetic risk factors in the host for
colonisation or invasion have yet been established [12].
Recognition, phagocytosis and complement
Fc-γ receptor polymorphisms
Antibodies against Neisseria meningitidis are important for
complement-mediated killing through the classical pathway
as well as for phagocytosis of the bacteria. Polymorphonu-
clear leucocytes possess three major classes of receptor for
the constant regions of IgG (FcγR): FcγRI (CD64), FcγRIIa
(CD 32) and FcγRIIIb (CD16). FcγRIIa is the only receptor
capable of binding IgG1, IgG2 as well as IgG3 [13]. Two
allotypic forms of this receptor are known, namely FcγRIIa-
H131 and FcγRIIa-R131, based on a single amino acid differ-
ence; these are respectively a histidine (H) or an arginine (R)
residue at position 131 [13]. Homozygous FcγRIIa-R/R131
are much less effective in binding IgG2 and are therefore less
effective in the phagocytosis of Neisseria meningitidis,
Haemophilus influenzae type b and Staphylococcus aureus
[14,15]. This allotype was present in 44% of children surviv-
ing a meningococcal septic shock, compared with 23% in a
healthy population [14]. Another study showed an associa-
tion between the FcγRIIa-R/R131 allotype and susceptibility
Figure 1
The possible involvement of genetic polymorphisms on the course of meningococcal disease. Partially adapted from [32].
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to meningococcal disease in individuals older than 5 years
[16]. However, this accounts for less than 30% of all
patients, because most pediatric patients suffering from
meningococcal disease are younger than 4 years. In all age
groups, a correlation was found between FcγRIIa allotype and
severity of meningococcal disease, indicated by a longer
duration of hospitalisation and a higher percentage of compli-
cations for patients with the FcγRIIa-R/R131 allotype. Neu-
trophils with the heterozygous allotype FcγRIIa-R/H131
showed intermediate levels of phagocytosis, resulting in inter-
mediate associations with susceptibility to and severity of
meningococcal disease [16]. The role of FcγR polymor-
phisms in complement-deficient individuals has been studied
extensively because these people depend heavily on phago-
cytosis in their defence against meningococci. The distribu-
tion of the different allotypes was no different in individuals
with late-complement-component deficiency (LCCD) from
that in the general population, but again the severity of
disease was positively correlated with the FcγRIIa-R/R131
allotype [17]. Thus, LCCD patients with this allotype are not
more susceptible to meningococcal disease, but owing to
ineffective phagocytosis their course of disease is signifi-
cantly more severe. However, the combination of FcγRIIa-
R/R131 and FcγRIIIb-NA2/NA2, which is another genotype
associated with a decreased capacity for phagocytosis by
neutrophils in vitro, was associated with a higher susceptibil-
ity to meningococcal disease of LCCD patients [18].
Complement deficiency
Activation of the complement cascade eventually lead to
the formation of a membrane attack complex, which results
in the lysis and cell death of the bacterium. In particular,
deficiencies of the alternative pathway and terminal compo-
nent deficiencies seem to have a large effect on suscepti-
bility to, as well as severity of, meningococcal disease,
emphasising the importance of the complement-dependent
defence against this particular pathogen. Individuals with
LCCD, for example, have a 7000–10,000-fold higher risk
of symptomatic meningococcal infections. However, mor-
tality rates of meningococcal disease in these patients are
much lower: 1.5% compared with 19% in the general pop-
ulation. Furthermore, the first episode of meningococcal
disease occurs at a median age of 17 years, whereas in the
general population the median age of occurrence is 3 years
[19]. Other complement-component deficiencies associ-
ated with an increased susceptibility to meningococcal
disease are deficiencies in properdin and factor D, both
components of the alternative pathway. Because no
genetic polymorphisms are known in these complement
components, detailed discussions about these diseases
will be omitted from this review.
Mannose-binding lectin polymorphisms
Specific antibodies, as well as proteins of the innate immune
system, can activate the complement system. One of these
innate pathways is activated by mannose-binding lectin
(MBL). This protein binds to sugars on microbial cell walls
and activates two mannose-binding-lectin-associated serine
proteases: MASP-1 and MASP-2 [20]. Defects in MBL can
result in impaired complement activation through this
pathway. The MBL gene determines the amount of MBL
present in plasma. Three variant alleles of exon 1 of this gene
have been identified [21–23]. Individuals who are homo-
zygous for one of these variants or carry two different variant
alleles have plasma concentrations of less than 1% of wild-
type concentrations, whereas heterozygotes have plasma
concentrations of about 10% [24]. A large study in children
with meningococcal disease revealed that the rates of
homozygous as well as heterozygous MBL variant genotypes
were much higher in patients than in controls (7.7% com-
pared with 1.5%, and 29.9% compared with 22.1% respec-
tively). Strikingly, the results of the same study suggested a
milder course of disease in individuals with variant genotypes,
as is also seen in individuals with LCCD [25]. However, MBL
variant genotypes are much more common than LCCD in the
general population (especially in African and Oriental popula-
tions) and could therefore account for a larger number of
meningococcal disease cases [21].
The role of LPS and signal transduction
Meningococcal LPS, which is released in enormous amounts
during meningococcal sepsis, consists of a polysaccharide
part and lipid A, which is responsible for the toxicity of the
molecule. LPS can bind to LPS-binding protein (LBP) which
is produced by hepatocytes and forms a complex [26]. This
complex is recognised by the LPS receptor CD14 on poly-
morphic nuclear neutrophils and macrophages [27]. The
CD14 receptor itself does not have a transmembrane part
and therefore cannot directly transduce the LPS signal [28].
It has been shown more recently that the Toll-like receptor 4
(TLR4) and its cofactor MD2 are essential in the process of
LPS signal transduction [29–31]. TLR4/MD-2 initiates the
LPS-induced cell response by signalling through the cell
membrane, by way of several signal pathways including acti-
vation of the nuclear factor NF-κβ, leading to gene replication
and the production of pro-inflammatory mediators in the cell
nucleus [32]. The response of TLR4/MD-2 on LPS is
enhanced by the presence of CD14 [28], but much is still
unknown about this process.
Theoretically, polymorphisms of the LBP gene could affect
the structure of LBP and therefore influence the host
defence against LPS. Two LBP genotypes have been
studied, in both of which a single nucleotide is exchanged
for another, resulting in a different amino acid: T292G
(Cys98→Gly) and C1306T (Pro436→Leu). No significant differ-
ences in the distribution of these genotypes were found
between a group of patients with sepsis and healthy con-
trols. However, there was a gender-related relationship
between the Cys98→Gly polymorphism and sepsis: a signifi-
cantly higher proportion of male patients had at least one
Gly98 allele than did the control group. It was suggested that
this unfavourable association might account for the worse
prognosis for male patients with sepsis than that for female
patients [33]. There is some evidence that common muta-
tions in the tlr4 gene are associated with LPS hyporespon-
siveness in humans [34]. In addition, an excess of rare amino
acid polymorphisms in the TLR4 have been shown to have a
deleterious effect in humans and are present at significantly
higher frequencies in patients with meningococcal sepsis
than in healthy individuals [35] (B. Beutler, personal commu-
nication). Furthermore, it has been shown that an LPS-defi-
cient mutant of Neisseria meningitidis is capable of inducing
the release of pro-inflammatory cytokines by macrophages
as a result of signalling via TLR2 [36]. Therefore, genetic
alterations in the tlr2 gene might also prove to be important
in influencing the response to LPS in humans.
Another protein with a high affinity for LPS is bactericidal/per-
meability-increasing protein (BPI), which is stored within neu-
trophilic granules and has been studied as an adjunctive
treatment drug for severe meningococcal sepsis [37]. Three
different polymorphisms of the BPI gene were studied as
well, but no significant difference in genotype distribution was
found between patients and controls [33]. It should be noted
that this study was undertaken in a general sepsis population
and the results might therefore not be representative of
meningococcal sepsis.
Cytokine response
Tumour necrosis factor-α
Mononuclear phagocytes release TNF-α upon stimulation
with LPS. The level of TNF-α varies greatly in patients with
meningococcal disease. The genetic influence on TNF-α
release has been shown clearly by several studies. For
example, Westendorp et al. [38] found that 60% of the varia-
tion in TNF-α production seems to be genetically deter-
mined. It has been assumed that a high level of circulating
TNF-α is associated with a severe course of disease [39].
However, those authors also found that family members of
non-survivors showed a low TNF and high production of
interleukin-10 (IL-10) when whole blood was stimulated with
LPS [38]. This suggests that an anti-inflammatory cytokine
genotype is unfavourable for the outcome of meningococcal
disease, which is in contrast with the association of high
TNF levels and the adverse outcome shown by other studies
[39,40]. A biallelic gene polymorphism in the restriction site
of NcpI within the gene encoding TNF-β is associated with a
high level of circulating TNF-α, but the influence of this poly-
morphism on the outcome in meningococcal sepsis is
unclear [41]. Furthermore, a genetic polymorphism has been
found in the promotor region of TNF-α, consisting of a single
base replacement at position –308 (guanosine versus
adenosine), but there is a lack of consensus about the rele-
vance of this polymorphism [42–44]. In summary, it is clear
that TNF-α production during meningococcal sepsis is
greatly influenced by genetic factors, but the impact of these
factors is still under discussion.
IL-1
The family of genes encoding IL-1 has several members: IL1A
and IL1B encode the pro-inflammatory mediators Il-1α and
IL-1β respectively, whereas IL1RN encodes the anti-inflam-
matory IL-1 receptor antagonist. Single-nucleotide polymor-
phisms occur in all these genes, resulting in biallelic
genotypes; these have been studied by Read et al. [43]. The
allelic distribution within IL1A had no significant conse-
quences, but individuals homozygous at position –511 within
IL1B were more likely to die from meningococcal disease.
Furthermore, individuals carrying the rare allele (either
homozygous or heterozygous) of IL1RN were also more likely
to die. A combination of these two genotypes leads to an
even higher mortality rate of up to 42% [43]. Another poly-
morphism within IL1RN, studied in a general sepsis popula-
tion, is located within intron 2, which contains a variable
number of base-pair repeats. Five different alleles can be
identified on the basis of the size of this repeat. The allele fre-
quency of IL-1raA2 was increased in patients with severe
sepsis compared with healthy individuals [45]. Thus, this
gene polymorphism might influence susceptibility to meningo-
coccal sepsis.
IL-6
IL-6 is a pro-inflammatory cytokine that is usually present in
high concentrations in patients with meningococcal sepsis. A
well-known polymorphism in the IL-6 promotor region is a
G→C transition at position –174. The G/G genotype is asso-
ciated with higher levels of IL-6 and this is correlated with
high mortality in general in patients with sepsis or septic
shock [46–48]. As with meningococcal disease, patients with
a G/G genotype had a threefold higher risk of death than
patients with all other genotypes [49]. This corresponds well
to the observation that higher levels of IL-6 are associated
with a fatal outcome of meningococcal disease [50]. No dif-
ferences in allele frequencies were found between patients
and healthy controls [49].
Haemostasis
Plasminogen-activator-inhibitor-1
An important fibrinolysis gene polymorphism associated with
meningococcal disease concerns plasminogen-activator-
inhibitor-1 (PAI-1), a protease secreted by endothelial cells,
thrombocytes and hepatocytes. It forms a complex with plas-
minogen activator, which is a proteolytic enzyme involved in
fibrinolysis. Meningococcal endotoxin induces extremely high
levels of PAI-1 in plasma, which can eventually lead to
massive coagulation. An intensively studied polymorphism
within the promotor region of the PAI-1 gene is a biallelic
single base-pair insertion/deletion polymorphism, resulting in
either four or five guanosine bases at position –675. The
homozygous 4G/4G genotype predisposes to higher PAI-1
concentrations on stimulation with IL-1β, and it has been
shown that the level of plasma PAI-1 is significantly higher in
non-survivors of meningococcal septic shock [51,52]. A
study by Hermans et al. [53] showed that a 4G/4G genotype
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in patients was associated with a twofold greater risk of death
from meningococcal disease compared with those with the
4G/5G or 5G/5G genotype. Susceptibility to disease was not
affected by the genotype [54]. The same association with
poor prognosis was found in severely injured patients after
trauma [55]. It seems that 4G/4G patients respond to various
stimuli with high PAI-1 levels, resulting in impaired fibrinolysis
and microcirculation; they therefore have a higher risk for mor-
tality. Many other polymorphisms concerning coagulation and
fibrinolysis are described in other reviews [56].
Conclusions and future perspectives
It is clear that host genetic factors can be important in the
various stages of meningococcal infections, but much is still
unknown about the genetic background of contracting
meningococcal disease. Genetic polymorphisms are com-
monly prevalent, and newly found polymorphisms will have to
be tested for their clinical relevance to susceptibility to and
severity of meningococcal disease. Possibly, gene polymor-
phisms also function at the important level of colonisation and
invasion of meningococci, which would make possible the
identification of individuals at high risk. In addition, it is most
likely that individuals with certain combinations of several
polymorphisms within the above-described genes have the
highest overall risk of dying from meningococcal disease. It is
therefore of great importance that molecular-genetic tech-
niques that can be easily and rapidly used in clinical practice
are implemented in the study of the interaction of multiple
polymorphisms in severe meningococcal infection.
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